Koninklijke Philips N.V.

Koninklijke Philips N.V.

PHG
Koninklijke Philips N.V.US flagNew York Stock Exchange
25.43
USD
-0.65
- -
24.21BMarket Cap
Koninklijke Philips N.V.
PHG
(New York Stock Exchange)

Recent

price

25.43

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
21.51
20.01
21.76
21.9
21.2
16.64
17.22
17.37
17.81
17.23
17.65
17.58
18.73
19.16
19.31
18.81
18.57
Revenue per Share
1.39
-1.39
-0.03
1.16
0.41
0.62
1.43
1.62
1.07
1.17
1.21
3.4
-1.69
-0.49
-0.75
0.94
1.02
Basic EPS, GAAP
1.95
-0.03
1.81
0.86
1.18
0.49
1.06
1.72
1.63
1.68
2.44
1.56
-0.29
2.15
1.55
1.09
2.29
Free Cash Flow per Basic Share
0.29
0.25
0.25
0.27
0.29
0.3
0.33
0.38
0.39
0.46
- -
0.49
0.43
- -
- -
0.35
0.35
Dividend per Share
15.07
12.47
10.68
8.08
7.44
8.15
8.27
8.58
8.31
8.51
8.17
9.76
7.36
5.89
4.11
3.97
4.11
Book Value per Share
2.76
1.28
0.5
1.45
0.44
-0.43
0.99
0.95
0.03
0.51
0.91
0.19
-0.51
-1.06
-1.42
-0.9
-0.92
Tangible Book Value per Share
1,036
1,049
1,022
1,004
1,009
1,010
1,012
1,024
1,017
995
981
976
952
948
933
948
950
Basic Weighted Avg Shares
22,287
20,992
22,234
21,990
21,391
16,806
17,421
17,780
18,121
17,147
17,312
17,156
17,827
18,169
18,021
17,834
17,643
Sales/Revenue/Turnover
9.31
4.17
2.66
8.56
2.29
3.92
8.42
7.99
9.13
8.11
8.11
3.63
-0.99
-0.92
2.85
8.12
8.72
Operating Margin (%)
1,343
1,400
1,242
1,177
1,187
972
976
1,025
1,089
1,343
1,462
1,323
1,602
1,261
1,389
1,124
1,112
Depreciation Expense
1,442
-1,460
-35
1,169
415
624
1,448
1,657
1,090
1,167
1,187
3,319
-1,608
-466
-702
895
970
Net Income, GAAP
25.45
- -
82.89
30.56
14.05
51.37
19.63
25.34
12.84
20.67
17.51
- -
- -
- -
782.93
23.86
23.66
Effective Tax Rate (%)
6.47
-6.96
-0.16
5.32
1.94
3.71
8.31
9.32
6.02
6.81
6.86
19.35
-9.02
-2.56
-3.9
5.02
5.5
Profit Margin (%)
3,839
3,109
2,573
2,998
3,715
2,734
3,602
3,252
1,629
2,481
3,493
2,898
2,325
1,654
1,878
2,421
2,352
Working Capital
2,818
3,278
3,725
3,309
3,712
4,095
4,021
3,468
3,238
4,876
5,590
5,737
7,017
6,959
7,048
6,811
6,891
LT Debt
15,092
12,350
11,185
11,227
10,968
11,780
13,453
12,023
12,117
12,625
11,901
14,475
13,283
12,061
12,043
10,989
11,418
Total Equity
7.92
- -
0.62
8.3
2.73
1.94
6.31
5.9
8.84
6.43
6.44
- -
- -
- -
-18.06
5.75
6.01
Return on Invested Capital (%)
8.27
- -
0.21
10.5
6.54
6.43
11.6
11.7
9.96
10.2
9.58
- -
- -
- -
-24.77
9.73
10.16
Return on Capital (%)
9.08
-10.18
-0.29
12.29
5.31
7.93
17.46
19.33
12.65
13.79
14.4
37.86
-19.45
-7.4
-14.9
23.53
24.8
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1,148
1,000
1,206
LT Borrowings
7,237
6,054
6,891
LT Finance Leases
- -
757
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
951
951
952
Market Capitalization
21,903
21,862
22,530

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
9,278
9,932
9,784
Cash, Cash Equivalents & STI
1,912
2,794
2,592
Accounts Receivable, Net
3,271
3,339
3,262
Inventories
3,260
2,870
3,110
Total Current Liabilities
7,030
7,511
7,432
Payables & Accruals
3,335
3,988
3,513
ST Debt
1,148
1,000
1,206
Deferred Revenue
1,522
1,490
1,617

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.19%
-0.94%
-8.75%
Free Cash Flow
-82.58%
-209.21%
-28.6%
Net Income, GAAP
-9.57%
-43.34%
-227.49%
Sales/Revenue/Turnover
0.63%
0.62%
-1.04%
Total Cash Common Dividend
8,058.07%
16,127.19%
32,700%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,138
4,462
4,377
5,044
18,021
2025
4,097
4,338
4,302
5,098
17,834
2026
3,905
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.07
0.47
0.19
-0.36
-0.75
2025
0.08
0.25
0.19
0.42
0.94
2026
0.16
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
0.31
0.03
- -
0.35
2026
- -
- -
- -
- -
- -
Business
Koninklijke Philips N.V. is a global health technology company headquartered in Amsterdam, Netherlands, founded in 1891. It operates mainly across the diagnosis and treatment, connected care, and personal health segments, offering a broad range of products and services including precision diagnostic imaging systems, image-guided therapy solutions, patient monitoring devices, health informatics, respiratory care, and personal health and home care products. Its core portfolio features advanced diagnostic imaging devices such as CT and ultrasound systems, AI-enabled clinical decision support tools, enterprise health informatics platforms, sleep and respiratory care solutions, and consumer health categories including grooming and oral healthcare devices. Philips serves markets primarily in North America, Western Europe, Greater China, and other growth geographies. Recent developments include the launch of the AI-powered Philips CT 5300 system, integrating advanced hardware and software with artificial intelligence to enhance imaging quality and boost clinical workflow efficiency. This system offers ultra-low dose screening capabilities and improved diagnostic confidence with smart workflow automation. Philips has also introduced two FDA-cleared AI applications for its Lumify point-of-care ultrasound system, enabling smarter, faster frontline care in anesthesia, emergency medicine, and critical care. Strategically, Philips has maintained cost discipline, restructuring its supply chain and reducing overhead while investing selectively in innovation projects. The company reported a reduced M&A spend in 2023 compared to 2022, focusing on operational improvements and cash preservation. Philips’ business model is arranged into global, end-to-end business units—Diagnosis & Treatment, Connected Care, and Personal Health—each managing their operations independently. Notably, the company is investing in improving productivity and operational efficiency with multi-year savings programs and enhanced product pipeline focus. Its recent partnerships include collaborations with healthcare institutions such as Hôpital Fondation Rothschild in Paris and Erasmus University Medical Center. Philips aims to improve 2.5 billion lives annually by 2030, reflecting its strategic commitment to health technology innovation and broad accessibility. Financially, Philips generated approximately $19.5 billion in revenue in 2024, employing around 67,800 people globally. The company continues to navigate challenges such as supply chain disruptions and market demand fluctuations, particularly in China, while driving growth in mature markets and leveraging AI and digital technologies to reinforce its competitive position in healthcare technology. Its leadership in diagnostic imaging, patient monitoring, connected care, and personal health makes it a key player in the global health technology industry.

Company News

APIChat
  • Here's Why Royal Philips (PHG) is a Strong Value Stock

  • Philips receives FDA 510(k) clearance for Elevate Plus for EPIQ Elite and Affiniti, delivering AI advancements in general imaging ultrasound

  • Philips announces exchange ratio for 2025 dividend

  • Philips announces exchange ratio for 2025 dividend

  • Here's Why Royal Philips (PHG) is a Strong Momentum Stock

  • Disney and Philips bring together beloved storytelling and innovative technology to support kids undergoing MRI exams

  • Philips Smart Locks Launch at Jarir Bookstore

  • Koninklijke Philips: AI Upside, And Margin Expansion Create An Attractive Entry Point

  • Philips highlights advances in imaging and physiology to support complex PCI at EuroPCR 2026

  • Philips highlights advances in imaging and physiology to support complex PCI at EuroPCR 2026

  • Philips introduces SmartIQ to address the trade-off between image quality and radiation dose in coronary procedures

  • Philips to deliver vital technology for hospital-at-home care for up to 15,000 patients annually in Region Stockholm

  • Philips to deliver vital technology for hospital-at-home care for up to 15,000 patients annually in Region Stockholm

  • Why Royal Philips (PHG) is a Top Value Stock for the Long-Term

  • Philips shareholders approve all proposals at the AGM 2026

  • Philips Q1 Earnings and Revenues Decrease Year over Year, Shares Up

  • PHG Breakdown, Earnings Beat & AI Outlook

  • Philips Reports Strong Order Intake Despite Uncertain Macro Environment

  • Koninklijke Philips N.V. (PHG) Q1 2026 Earnings Call Transcript

  • Philips CEO: We will ask Trump administraton for tariff rebate